Control of spasticity in a multiple sclerosis model using central nervous system-excluded CB1 cannabinoid receptor agonists.
Pryce G, Visintin C, Ramagopalan SV, Al-Izki S, De Faveri LE, Nuamah RA, Mein CA, Montpetit A, Hardcastle AJ, Kooij G, de Vries HE, Amor S, Thomas SA, Ledent C, Marsicano G, Lutz B, Thompson AJ, Selwood DL, Giovannoni G, Baker D.
Pryce G, et al.
FASEB J. 2014 Jan;28(1):117-30. doi: 10.1096/fj.13-239442. Epub 2013 Oct 11.
FASEB J. 2014.
PMID: 24121462